Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study

PURPOSE: We performed a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with histologically confirmed measurable advanced HCC and adequate hematologic, hepatic, and renal functions...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Zhu, Andrew X., Ancukiewicz, Marek, Supko, Jeffrey G., Sahani, Dushyant V., Blaszkowsky, Lawrence S., Meyerhardt, Jeffrey A., Abrams, Thomas A., McCleary, Nadine Jackson, Bhargava, Pankaj, Muzikansky, Alona, Sheehan, Susan, Regan, Eileen, Vasudev, Eamala, Knowles, Michelle, Fuchs, Charles S., Ryan, David P., Jain, Rakesh K., Duda, Dan G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3609423/
https://ncbi.nlm.nih.gov/pubmed/23362324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3041
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi